Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation
- 1 March 1993
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 71 (7) , 558-563
- https://doi.org/10.1016/0002-9149(93)90511-a
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.Circulation, 1990
- Therapeutic efficacy and safety of oral propafenone for atrial fibrillationThe American Journal of Cardiology, 1989
- Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutterJournal of the American College of Cardiology, 1988
- Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up studyEuropean Heart Journal, 1988
- Propafenone for paroxysmal atrial fibrillationThe American Journal of Cardiology, 1988
- Sotalol: A beta blocker with unique antiarrhythmic propertiesAmerican Heart Journal, 1987
- Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm.Heart, 1975
- Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversionClinical Pharmacology & Therapeutics, 1974
- Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation. A controlled clinical study.Heart, 1971
- Maintenance of sinus rhythm after DC reversion of atrial fibrillation: A double-blind controlled trial of long-acting quinidine bisulphateHeart, 1970